| Literature DB >> 23348994 |
Abstract
The ethanol extract of the whole plants of Viburnum mongolicum afforded six new nor-dammarane triterpenoids: 3β,12β-dihydroxy-25,26,27-trinordammara-22-en -24,20-olide (1), 3β,12β-dihydroxy-24α-methoxy-25,26,27-trinordammara-20,24-epoxy (2), 3β-O-acetyl-12β-hydroxy-23,24,25,26,27-hexanordammarane-20-one (3), 12β-O- acetyl-15α-hydroxy-17β-methoxy-3-oxo-20,21,22-23,24,25,26,27-octanordammanrane (4), 12β-O-acetyl-15α,17β-dihydroxy-3-oxo-20,21,22-23,24,25,26,27-octanordammanrane (5), and 12β,15α-dihydroxy-3-oxo-17-en-20,21,22-23,24,25,26,27-octanordammanrane (6), together with two known nor-dammarane triterpenoids, 12β-hydroxy-3-oxo-24α-methoxy- 25,26,27-trinordammara-20,24-epoxy (7) and 3β,12β-dihydroxy-23,24,25,26,27- hexanordammarane-20-one (8). The structures of the isolated compounds were established based on 1D and 2D (¹H-¹H COSY, HMQC, and HMBC) NMR spectroscopy, in addition to high resolution mass spectrometry. The isolated compounds were tested in vitro for cytotoxic potential against seven tumor cell lines and radical scavenging activities. Compounds 4-6 exhibited significant cytotoxic activities against all tested tumor cell lines and radical scavenging activities against ABTS·+ radicals comparable with the standard drug Trolox.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23348994 PMCID: PMC6269952 DOI: 10.3390/molecules18021405
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–8.
1H-NMR data of compounds 1–6 in CDCl3 (δ in ppm and J in Hz).
| No. | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1ax | 1.03 ( | 1.00 ( | 1.02 ( | 1.47 ( | 1.44 ( | 1.45 ( |
| 1eq | 1.69 ( | 1.66 ( | 1.68 ( | 1.95 ( | 1.94 ( | 1.93 ( |
| 2ax | 1.59 ( | 1.56 ( | 1.59 ( | 2.38 ( | 2.36 ( | 2.39 ( |
| 2eq | 1.67 ( | 1.64 ( | 1.66 ( | 2.52 ( | 2.48 ( | 2.47 ( |
| 3 | 3.21 ( | 3.17 ( | 4.39 ( | - | - | - |
| 5 | 0.78 ( | 0.76 ( | 0.79 ( | 1.37 ( | 1.35 ( | 1.36 ( |
| 6ax | 1.47 ( | 1.46 ( | 1.48 ( | 1.44 ( | 1.42 ( | 1.48 ( |
| 6eq | 1.62 ( | 1.58 ( | 1.60 ( | 1.58 ( | 1.56 ( | 1.59 ( |
| 7ax | 1.58 ( | 1.55 ( | 1.57 ( | 1.54 ( | 1.53 ( | 1.54 ( |
| 7eq | 2.18 ( | 2.15 ( | 2.17 ( | 2.20 ( | 2.18 ( | 2.19 ( |
| 9 | 1.55 ( | 1.53 ( | 1.55 ( | 1.51 ( | 1.49 ( | 1.52 ( |
| 11ax | 1.27 ( | 1.26 ( | 1.27 ( | 1.27 ( | 1.26 ( | 1.24 ( |
| 11eq | 1.84 ( | 1.87 ( | 1.89 ( | 1.92 ( | 1.91 ( | 1.84 ( |
| 12 | 3.62 ( | 3.47 ( | 3.49 ( | 4.47 ( | 4.44 ( | 3.80 ( |
| 13 | 1.44 ( | 2.16 ( | 2.08 ( | 2.12 ( | 2.11 ( | 2.78 ( |
| 15ax | 1.17 ( | 1.76 ( | 1.21 ( | 3.48 ( | 3.44 ( | 4.55 ( |
| 15eq | 1.56 ( | 1.77 ( | 1.68 ( | - | - | - |
| 16ax | 1.80 ( | 1.70 ( | 1.72 ( | 2.02 ( | 1.98 ( | 5.63 ( |
| 16eq | 2.05 ( | 2.02 ( | 2.04 ( | 2.35 ( | 2.32 ( | - |
| 17 | 2.29 ( | 2.22 ( | 2.88 ( | 3.98 ( | 4.23 ( | 6.62 ( |
| 18 | 0.91 ( | 0.96 ( | 1.06 ( | 0.87 ( | 0.85 ( | 0.89 ( |
| 19 | 0.89 ( | 0.93 ( | 0.99 ( | 0.99 ( | 0.96 ( | 0.98 ( |
| 21 | 1.45 ( | 1.35 ( | 2.24 ( | - | - | - |
| 22ax | 7.86 ( | 1.84 ( | - | - | - | - |
| 22eq | - | 1.95( | - | - | - | - |
| 23ax | 6.06 ( | 1.98 ( | - | - | - | - |
| 23eq | - | 2.05( | - | - | - | - |
| 24 | - | 4.93 ( | - | - | - | - |
| 28 | 0.79 ( | 0.77 ( | 0.78 ( | 0.79 ( | 0.77 ( | 0.78 ( |
| 29 | 0.99 ( | 0.97 ( | 0.98 ( | 1.01 ( | 0.98 ( | 1.03 ( |
| 30 | 0.84 ( | 0.89 ( | 0.91 ( | 1.24 ( | 1.19 ( | 1.26 ( |
| - | - | 2.01 ( | 2.10 ( | 2.08 ( | - | |
| O
| - | 3.26 ( | - | 3.21 ( | - | - |
Figure 2Key HMBC () and 1H-1H COSY () correlations of compounds 1, 3 and 4.
13C-NMR data of compounds 1–6 in CDCl3.
| No. | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1 | 38.8 ( | 38.8 ( | 39.0 ( | 40.1 ( | 39.6 ( | 39.6 ( |
| 2 | 27.1 ( | 27.1 ( | 27.2 ( | 34.2 ( | 33.9 ( | 33.8 ( |
| 3 | 78.5 ( | 78.4 ( | 81.3 ( | 218.8 ( | 218.7 ( | 219.2 ( |
| 4 | 38.9 ( | 38.8 ( | 38.9 ( | 47.6 ( | 47.2 ( | 47.7 ( |
| 5 | 55.6 ( | 56.0 ( | 56.0 ( | 55.5 ( | 55.2 ( | 55.8 ( |
| 6 | 17.8 ( | 17.9 ( | 18.0 ( | 19.7 ( | 20.2 ( | 20.1( |
| 7 | 32.8 ( | 33.4 ( | 33.3 ( | 34.6 ( | 34.5 ( | 35.1 ( |
| 8 | 39.8 ( | 39.0 ( | 39.0 ( | 39.9 ( | 39.8 ( | 39.7 ( |
| 9 | 50.1 ( | 50.8 ( | 51.0 ( | 50.1 ( | 49.9 ( | 49.7 ( |
| 10 | 37.4 ( | 37.7 ( | 37.5 ( | 37.2 ( | 36.7 ( | 37.3 ( |
| 11 | 32.3 ( | 32.7 ( | 32.4 ( | 32.7 ( | 32.1 ( | 35.8 ( |
| 12 | 70.7 ( | 71.9 ( | 71.2 ( | 73.1 ( | 72.9 ( | 71.0 ( |
| 13 | 49.6 ( | 50.9 ( | 50.9 ( | 47.7 ( | 47.4 ( | 58.1 ( |
| 14 | 51.7 ( | 53.3 ( | 51.1 ( | 55.3 ( | 54.8 ( | 60.3 ( |
| 15 | 31.1 ( | 33.2 ( | 31.8 ( | 69.9 ( | 69.4 ( | 68.0 ( |
| 16 | 26.4 ( | 31.1 ( | 26.8 ( | 39.4 ( | 39.0 ( | 132.1 ( |
| 17 | 47.0 ( | 50.7 ( | 52.9 ( | 76.4 ( | 71.5 ( | 158.8 ( |
| 18 | 14.8 ( | 15.6 ( | 15.2 ( | 16.1 ( | 16.2 ( | 16.0 ( |
| 19 | 15.6 ( | 16.7 ( | 16.0 ( | 18.9 ( | 18.8 ( | 20.5 ( |
| 20 | 91.7 ( | 80.4 ( | 215.4 ( | - | - | - |
| 21 | 22.5 ( | 30.5 ( | 29.4 ( | - | - | - |
| 22 | 161.3 ( | 29.2 ( | - | - | - | - |
| 23 | 120.5 ( | 33.8 ( | - | - | - | - |
| 24 | 172.1 ( | 107.5 ( | - | - | - | - |
| 28 | 15.4 ( | 15.2 ( | 15.3 ( | 16.0 ( | 15.9 ( | 15.9 ( |
| 29 | 28.0 ( | 27.9 ( | 28.0 ( | 28.1 ( | 28.0 ( | 28.0 ( |
| 30 | 17.2 ( | 17.9 ( | 16.7 ( | 16.2 ( | 14.9 ( | 19.9 ( |
| C=O | - | - | 172.9 ( | 173.1 ( | 172.6 ( | - |
| Me | - | - | 21.7 ( | 22.1 ( | 21.3 ( | - |
| OMe | - | 55.4 ( | - | 58.6 ( | - | - |
Cytotoxicity of compounds 1–8 against seven human tumor cell lines (IC50, μM) a.
| Cell lines | |||||||
|---|---|---|---|---|---|---|---|
| A-549 | BGC-823 | HepG2 | HL-60 | MCF-7 | SMMC-7721 | W480 | |
| 79.4 | 80.3 | 80.2 | 78.8 | 81.8 | 80.5 | 81.6 | |
| 29.7 | 29.6 | 29.4 | 29.4 | 27.1 | 30.1 | 24.9 | |
| 63.2 | 66.8 | 51.1 | 68.2 | 53.5 | 50.1 | 59.7 | |
| 12.3 | 15.9 | 14.3 | 17.0 | 15.1 | 14.7 | 17.1 | |
| 12.7 | 12.2 | 12.8 | 13.8 | 11.3 | 11.7 | 18.3 | |
| 14.3 | 9.4 | 10.1 | 11.1 | 10.4 | 9.7 | 19.1 | |
| 31.9 | 31.2 | 30.7 | 32.2 | 28.1 | 29.9 | 27.6 | |
| 76.3 | 68.7 | 66.9 | 72.3 | 76.2 | 70.8 | 69.4 | |
| Doxorubicin | 18.3 | 14.7 | 22.0 | 31.7 | 24.9 | 35.4 | 15.9 |
a Doxorubicin activities are expressed as IC50 values in nM, and those of compounds 1–8 are expressed as IC50 values in μM. (-) IC50 > 100 μM.
Free radical scavenging activity of compounds 1–8 evaluated with DPPH, ABTS·+ assays (IC50, μM).
| DPPH IC50 | ABTS·+ IC50 | |
|---|---|---|
| 276.8 ± 5 | 309.1 ± 6 | |
| 253.1 ± 5 | 241.0 ± 5 | |
| 244.7 ± 5 | 256.1 ± 5 | |
| 101.3 ± 4 | 68.1 ± 4 | |
| 99.7 ± 3 | 59.2 ± 3 | |
| 94.1 ± 3 | 54.6 ± 3 | |
| 261.4 ± 5 | 299.1 ± 5 | |
| 241.0 ± 5 | 271.3 ± 6 | |
| Trolox | 42.8 ± 1 | 80.1 ± 3 |